ASX:ATX

Amplia Therapeutics Competitors

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume77,249 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Amplia Therapeutics (ASX:ATX) Vs. CHV, DDXS, PREV, TNGN, COM, and MYM

Should you be buying ATX stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Amplia Therapeutics, including (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), and 17031 (MYM).

Amplia Therapeutics (ASX:ATX) and (CHV) (CNSX:CHV) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.

Profitability

This table compares Amplia Therapeutics and (CHV)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amplia TherapeuticsN/AN/AN/A
(CHV)N/AN/AN/A

Earnings & Valuation

This table compares Amplia Therapeutics and (CHV)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amplia Therapeutics$894,155.000.00$-3,023,244.00A($0.03)N/A
(CHV)N/AN/AN/AN/AN/A

(CHV) has lower revenue, but higher earnings than Amplia Therapeutics.

Analyst Recommendations

This is a breakdown of recent ratings for Amplia Therapeutics and (CHV), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amplia Therapeutics0000N/A
(CHV)0000N/A

Summary

Amplia Therapeutics beats (CHV) on 1 of the 1 factors compared between the two stocks.

Amplia Therapeutics (ASX:ATX) and (DDXS) (OTCMKTS:DDXS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.

Analyst Recommendations

This is a breakdown of recent ratings for Amplia Therapeutics and (DDXS), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amplia Therapeutics0000N/A
(DDXS)0000N/A

Earnings & Valuation

This table compares Amplia Therapeutics and (DDXS)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amplia Therapeutics$894,155.000.00$-3,023,244.00A($0.03)N/A
(DDXS)N/AN/AN/AN/AN/A

(DDXS) has lower revenue, but higher earnings than Amplia Therapeutics.

Profitability

This table compares Amplia Therapeutics and (DDXS)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amplia TherapeuticsN/AN/AN/A
(DDXS)N/AN/AN/A

Summary

Amplia Therapeutics beats (DDXS) on 1 of the 1 factors compared between the two stocks.

(PREV) (CNSX:PREV) and Amplia Therapeutics (ASX:ATX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, profitability, valuation and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for (PREV) and Amplia Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
(PREV)0000N/A
Amplia Therapeutics0000N/A

Earnings and Valuation

This table compares (PREV) and Amplia Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
(PREV)N/AN/AN/AN/AN/A
Amplia Therapeutics$894,155.000.00$-3,023,244.00A($0.03)N/A

(PREV) has higher earnings, but lower revenue than Amplia Therapeutics.

Profitability

This table compares (PREV) and Amplia Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
(PREV)N/AN/AN/A
Amplia TherapeuticsN/AN/AN/A

Summary

Amplia Therapeutics beats (PREV) on 1 of the 1 factors compared between the two stocks.

(TNGN) (OTCMKTS:TNGN) and Amplia Therapeutics (ASX:ATX) are both health technology companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, profitability, valuation and earnings.

Earnings and Valuation

This table compares (TNGN) and Amplia Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
(TNGN)N/AN/AN/AN/AN/A
Amplia Therapeutics$894,155.000.00$-3,023,244.00A($0.03)N/A

(TNGN) has higher earnings, but lower revenue than Amplia Therapeutics.

Profitability

This table compares (TNGN) and Amplia Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
(TNGN)N/AN/AN/A
Amplia TherapeuticsN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for (TNGN) and Amplia Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
(TNGN)0000N/A
Amplia Therapeutics0000N/A

Summary

Amplia Therapeutics beats (TNGN) on 1 of the 1 factors compared between the two stocks.

138267 (COM.TO) (TSE:COM) and Amplia Therapeutics (ASX:ATX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Earnings & Valuation

This table compares 138267 (COM.TO) and Amplia Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
138267 (COM.TO)N/AN/AN/AN/AN/A
Amplia Therapeutics$894,155.000.00$-3,023,244.00A($0.03)N/A

138267 (COM.TO) has higher earnings, but lower revenue than Amplia Therapeutics.

Profitability

This table compares 138267 (COM.TO) and Amplia Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
138267 (COM.TO)N/AN/AN/A
Amplia TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and price targets for 138267 (COM.TO) and Amplia Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
138267 (COM.TO)0000N/A
Amplia Therapeutics0000N/A

Summary

Amplia Therapeutics beats 138267 (COM.TO) on 1 of the 1 factors compared between the two stocks.

17031 (CNSX:MYM) and Amplia Therapeutics (ASX:ATX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Earnings & Valuation

This table compares 17031 and Amplia Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
17031N/AN/AN/AN/AN/A
Amplia Therapeutics$894,155.000.00$-3,023,244.00A($0.03)N/A

17031 has higher earnings, but lower revenue than Amplia Therapeutics.

Profitability

This table compares 17031 and Amplia Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
17031N/AN/AN/A
Amplia TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and price targets for 17031 and Amplia Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
170310000N/A
Amplia Therapeutics0000N/A

Summary

Amplia Therapeutics beats 17031 on 1 of the 1 factors compared between the two stocks.


Amplia Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
(DDXS) logo
DDXS
(DDXS)
0.5$0.00flat$0.00N/A0.00
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
TNGN
(TNGN)
0.4N/AN/A$0.00N/A0.00Gap Up
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
Abattis Bioceuticals logo
ATTBF
Abattis Bioceuticals
0.4$0.02flat$0.00N/A0.00
Abzena logo
ABZA
Abzena
0.6$15.75flat£0.00N/A0.00
ACR
Acrux
0.9N/AN/A$0.00$1.61 million0.00High Trading Volume
Gap Up
ACW
Actinogen Medical
0.5N/AN/A$0.00$2.84 million0.00High Trading Volume
Gap Up
1AD
AdAlta
0.5N/AN/A$0.00$4.23 million0.00High Trading Volume
Gap Up
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.52flat$0.00N/A0.00
AHZ
Admedus
0.5N/AN/A$0.00N/A0.00High Trading Volume
Algernon Pharmaceuticals logo
AGNPF
Algernon Pharmaceuticals
0.0$0.12flat$0.00N/A0.00Gap Down
Almirall logo
LBTSF
Almirall
0.5$15.15flat$0.00N/A0.00
AMBS
Amarantus BioScience
0.5N/AN/A$0.00N/A0.00High Trading Volume
ANR
Anatara Lifesciences
0.5N/AN/A$0.00$268,259.000.00High Trading Volume
Gap Up
ANVS
Annovis Bio
0.0N/AN/A$0.00N/A0.00High Trading Volume
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.07flat$0.00N/A0.00Gap Up
ARNI
Arno Therapeutics
0.5$0.01flat$0.00N/A0.00Gap Up
ASCLF
Ascletis Pharma
0.4$0.37flat$0.00N/A0.00
Avid Bioservices logo
CDMOP
Avid Bioservices
0.3$25.06flat$0.00N/A0.00
AXIM Biotechnologies logo
AXIM
AXIM Biotechnologies
0.4$0.56flat$0.00N/A0.00
BXRXV
Baudax Bio
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
BerGenBio ASA logo
BRRGF
BerGenBio ASA
0.7$3.52flat$0.00N/A0.00News Coverage
BGT
Bio-Gene Technology
0.8N/AN/A$0.00$82,795.000.00High Trading Volume
Gap Up
BMEA
Biomea Fusion
0.0$16.79flat$0.00N/A0.00High Trading Volume
Gap Up
BNO
Bionomics
0.5N/AN/A$0.00$2.19 million0.00High Trading Volume
Gap Up
BIT
Biotron
0.5N/AN/A$0.00$853,026.000.00High Trading Volume
Gap Up
BXN
Bioxyne
0.5N/AN/A$0.00$2.18 million0.00High Trading Volume
Gap Up
BOT
Botanix Pharmaceuticals
0.5N/AN/A$0.00$6.89 million0.00High Trading Volume
News Coverage
Gap Up
BPH
BPH Energy
0.5N/AN/A$0.00$106,954.000.00High Trading Volume
News Coverage
Gap Up
BTC
BTC Health
0.8N/AN/A$0.00$131,934.000.00High Trading Volume
Gap Up
Cannabics Pharmaceuticals logo
CNBX
Cannabics Pharmaceuticals
0.4$0.18flat$0.00N/A0.00News Coverage
ORHOF
CannaRoyalty
0.7$9.23flat$0.00N/A0.00Gap Down
CDXI
Cardax
0.0N/AN/A$0.00N/A0.00High Trading Volume
CDY
Cellmid
0.5N/AN/A$0.00$6.61 million0.00High Trading Volume
Gap Up
Cerebain Biotech logo
CBBT
Cerebain Biotech
0.0$0.03flat$0.00N/A0.00Gap Up
CHM
Chimeric Therapeutics
0.3N/AN/A$0.00N/A0.00High Trading Volume
CGYG
China Longyi Group International
0.4$0.00flat$0.00N/A0.00
CLVLY
Clinuvel Pharmaceuticals
1.0$23.20flat$0.00N/A0.00
CUV
Clinuvel Pharmaceuticals
1.0N/AN/A$0.00$38.34 million0.00High Trading Volume
Gap Up
CELZ
Creative Medical Technology
0.5$0.03flat$0.00N/A0.00Gap Up
CSL logo
CSL
CSL
0.8N/AN/A$0.00$9.98 billion0.00High Trading Volume
Gap Up
Cybin logo
CLXPF
Cybin
0.7$1.17flat$0.00N/A0.00News Coverage
CYP
Cynata Therapeutics
0.5N/AN/A$0.00$2.59 million0.00High Trading Volume
Gap Up
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
Eastgate Biotech logo
ETBI
Eastgate Biotech
0.5$0.01flat$0.00N/A0.00Gap Down
EMMBF
Emblem
0.6$1.40flat$0.00N/A0.00
ENZC
Enzolytics
0.0$0.14flat$0.00N/A0.00High Trading Volume
News Coverage
Gap Down
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected]m | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.